目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED FOR THE STUDY
1.5 CURRENCY
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.8.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 GROWTH FORECAST
2.4.3 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 MARKET SHARE ANALYSIS
2.7 STUDY ASSUMPTIONS
2.8 RISK ASSESSMENT
2.9 LIMITATIONS
2.1 RECESSION IMPACT: CLINICAL CHEMISTRY ANALYZERS MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 PRICING ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.8 REGULATORY LANDSCAPE
5.9 PESTLE ANALYSIS
5.10 TRADE ANALYSIS
5.11 PATENT ANALYSIS

6 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT (USD MILLION)
6.1 INTRODUCTION
6.2 REAGENTS
6.3 ANALYZERS
6.3.1 SEMI AUTOMATIC ANALYSERS
6.3.2 FULLY AUTOMATIC ANALYZERS
6.3.3 POINT-OF-CARE ANALYZERS
6.4 OTHER PRODUCTS

7 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE (USD MILLION)
7.1 INTRODUCTION
7.2 BASIC METABOLIC PANEL
7.3 LIVER PANEL
7.4 RENAL PROFILE
7.5 LIPID PROFILE
7.6 THYROID FUNCTION PANEL
7.7 ELECTROLYTE PANEL
7.8 SPECIALTY CHEMICAL TESTS

8 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER (USD MILLION)
8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 DIAGNOSTIC LABORATROIES
8.4 RESEARCH LABORATORIES & INSTITUTES
8.5 OTHER END USERS

9 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 RECESSION IMPACT
9.2.2 US
9.2.3 CANADA
9.3 EUROPE
9.2.1 RECESSION IMPACT
9.3.2 UK
9.3.3 GERMANY
9.3.4 FRANCE
9.3.5 ITALY
9.3.6 SPAIN
9.3.7 RUSSIA
9.3.8 REST OF EUROPE (ROE)
9.4 ASIA PACIFIC
9.4.1 RECESSION IMPACT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 REST OF ASIA PACIFIC (ROAPAC)
9.5 LATIN AMERICA
9.5.1 RECESSION IMPACT
9.6 MIDDLE EAST AND AFRICA
9.6.1 RECESSION IMPACT

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
10.7 COMPANY FOOTPRINT ANALYSIS
10.7.1 COMPANY FOOTPRINT
10.7.2 COMPANY REGIONAL FOOTPRINT
10.7.3 COMPANY PRODUCT FOOTPRINT
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
10.8.2 DEALS
10.8.3 EXPANSIONS

11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 KEY PLAYERS
11.1.1 ABBOTT LABORATORIES
11.1.2 DANAHER CORPORATION
11.1.3 SIEMENS HEALTHINEERS AG
11.1.4 THERMO FISHER SCIENTIFIC INC.
11.1.5 F. HOFFMANN-LA ROCHE LTD.
11.1.6 HORIBA LTD.
11.1.7 SYSMEX CORPORATION
11.1.8 EKF DIAGNOSTICS
11.1.9 HITACHI
11.1.10 QUIDELORTHO CORPORATION
11.2 OTHER PLAYERS
11.1.1 ELITECH GROUP
11.1.2 MINDRAY MEDICAL INTERNATIONAL LTD.
11.1.3 BIOBASE GROUP
11.1.4 SFRI MEDICAL DIAGNOSTIC
11.1.5 TRIVITRON HEALTHCARE PVT. LTD.
11.1.6 RANDOX LABORATORIES LTD.
11.1.7 MEDICA CORPORATION
11.1.8 MERIL LIFE SCIENCES PVT. LTD.
11.1.9 ERBA MANNHEIM
11.1.10 GENRUI BIOTECH INC.
11.1.11 DIRUI INDUSTRIAL CO. LTD.
11.1.12 TECO DIAGNOSTICS
11.1.13 BALIO DIAGNOSTICS
11.1.14 SNIBE CO. LTD.
11.1.15 AMS ALLIANCE
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX
12.1 INDUSTRY INSIGHTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS